Tina Vilsbøll - Concepedia

Author

Tina Vilsbøll

Also Known As

ADA/EASD PMDI, Antonio Nicolucci, C. Lush, Kimberly K. Vesco, M. Newman, Miriam S. Udler, Paul W. Franks, Rasmussen S, T Vilsboll, T Vilsbøll

719

Publications

34.9K

Citations

H-Index

117

Concepts

All Affiliations

University of Copenhagen Gentofte Hospital Steno Diabetes Centers Novo Nordisk Foundation Rigshospitalet

About

Tina Vilsbøll is an author at University of Copenhagen specializing in medicine, diabetes, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	61	5.9K
2	Health Sciences	24	33	3.5K
3	Public Health	5	5	100
4	Biochemistry	5	5	99
5	Allergy	2	2	230

Tina Vilsbøll

238

Publications

20K

Citations

H-Index

Page 1

	Year	Citations
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, New England Journal of Medicine	2019	1.8K
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients Tina Vilsbøll, Thure Krarup, Carolyn F. Deacon, Diabetes	2001	877
Recovery of gut microbiota of healthy adults following antibiotic exposure Albert Pallejá, Sofia K. Forslund, Alireza Kashani, Nature Microbiology ProbioticDysbiosisMicrobiotaGut MicrobiologyGut Microbiota	2018	805
Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus Tina Vilsbøll, Thure Krarup, Jesper Sonne, The Journal of Clinical Endocrinology & Metabolism NutritionHealthy SubjectsIncretin SecretionInsulin SignalingGastrointestinal Peptide Hormone	2003	515
Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes Tina Vilsbøll, Milan Zdravkovic, T Le-Thi, Diabetes Care	2007	467
Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects Tina Vilsbøll, Henrik Agersø, Thure Krarup, The Journal of Clinical Endocrinology & Metabolism NutritionHealthy SubjectsInsulin SignalingGastrointestinal Peptide HormoneObesity	2003	437
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects Tina Vilsbøll, Thure Krarup, Sten Madsbad, Regulatory Peptides Metabolic SyndromeGastrointestinal Peptide HormoneHealthy SubjectsPostprandial Glucose LevelsInsulin Management	2003	421
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes Patricia V. Højberg, Tina Vilsbøll, Rasmus Rabøl, Diabetologia Metabolic SyndromeInsulin SignalingDiabetes ManagementInsulin ManagementPhysiology	2008	408
Reduced Incretin Effect in Type 2 Diabetes Filip K. Knop, Tina Vilsbøll, Patricia V. Højberg, Diabetes	2007	345
Glucose-Dependent Insulinotropic Polypeptide Mikkel Christensen, Louise Vedtofte, Jens J. Holst, Diabetes	2011	338

Page 1